Innoxa has sold its eye care activity to Biosynex Group
June 2023 — The private shareholders of Laboratoires Innoxa have sold the company’s eye care activity to Biosynex Group.
Founded in 1920 in Paris by Dr. François Debat, a French pharmacist, Laboratoires Innoxa is a premium brand recognized worldwide for its expertise in the field of ophthalmology and optics. In 2020, the company was acquired by Frédéric and Laetitia Poux, who conducted a complete refoundation of the portfolio. The brand launched its first products in September 2021 and a new patented best-seller – the blue eye drops – in June 2022. Innoxa’s eye care activity now includes seven references with patented formulas, which comply with the latest European health and safety standards. The company’s product portfolio is structured around four areas: eye drops, eye sprays, contactology and optical sprays. The brand distributes its products in several countries, mostly in Europe and Asia, with core markets in France and China. Innoxa has a multichannel strategy with a historical presence in pharmacies and a focus on online platforms such as Amazon.fr and e-parapharmacies.
Founded in 2005, Biosynex is a leading public health player in France and Europe. The group offers innovative healthcare solutions to a wide range of users through two divisions: Biosynex Pharma (specialized in self-diagnostics and family health products) and Biosybex Diagnostic (developing and offering in vitro diagnostic medical devices). The group employs over 500 people, has a presence in 95 countries, and generated approximately US$212 in sales in 2022.
Our role in the transaction
Oaklins’ team in France acted as M&A advisor to Laboratoires Innoxa in this transaction.
Prata med transaktionsteamet
Relaterade transaktioner
Mattina Holding has sold a 5% stake in Gens Aurea via accelerated bookbuild
Mattina Holding S.A. (DVC Partners) has sold a 5% stake in Italian company Gens Aurea S.p.A. through an accelerated bookbuild, raising approximately US$69.96 million.
Lär dig merTNT has been acquired by PM Studio
TNT Group has been acquired by PM Studio Group, backed by Andera Partners, bringing together two complementary specialists in premium packaging for the beauty and luxury industries. TNT’s expertise in bespoke primary packaging complements PM Studio’s secondary packaging, gifting and creative design capabilities, creating a broader, integrated offering for major luxury brands. The transaction strengthens the group’s geographical footprint in Asia and the USA, diversifying its customer portfolio. The combined group generates over US$145 million in revenue and has approximately 150 employees worldwide. Following the transition of operational leadership to CEO Damon Kennish, the founders completed the sale to PM Studio while making a significant reinvestment alongside the management team, demonstrating their confidence in the combined group’s long-term potential. It aims to reach US$280 million in revenue by 2029 through organic growth, commercial synergies and further acquisitions.
Lär dig merKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Lär dig mer